Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 20/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 20/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 1.00 |
| ▸ | HRH1 | P35367 | 4/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | MLNR | O43193 | 1/20 | 0.66 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182179 | 0.96 | SLC6A2 (0.92) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3199883 | 0.96 | SLC6A2 (0.92) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3327900 | 0.93 | SLC6A2 (0.88) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3333592 | 0.93 | SLC6A2 (0.86) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3333367 | 0.93 | SLC6A2 (0.86) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3333370 | 0.93 | SLC6A2 (0.86) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| Hydrochloric Acid SCHEMBL3327420 | 0.92 | SLC6A2 (0.84) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| Hydrochloric Acid SCHEMBL3327424 | 0.92 | SLC6A2 (0.84) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL5307937 | 0.90 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL30510969 | 0.90 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1744754-A1 | MORPHOLINE COMPOUNDS | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | claimed |
| WO-2005105100-A1 | MORPHOLINE COMPOUNDS | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | claimed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| EP-1744754-A1 | MORPHOLINE COMPOUNDS | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | disclosed |
| US-20050250775-A1 | Novel compounds | FISH PAUL V | 2005-11-10 | — | — | US | disclosed |
| WO-2005105100-A1 | MORPHOLINE COMPOUNDS | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250775-A1 | Novel compounds | OPRL1, UGT1A1, NPSR1 | SLC6A2 133/4885SLC6A4 114/4885SLC6A3 104/4885 |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | OPRL1, MYLK2, TNNT2 | SLC6A2 201/4885SLC6A4 350/4885SLC6A3 729/4885 |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | SLC6A2 109/4885SLC6A4 113/4885SLC6A3 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.